Novartis says buoyed by new treatments in second quarter / Photo: GABRIEL MONNET - AFP
-
$1.8 Billion Pledged for Biodiversity at COP17 as Monaco Reaffirms Commitment
-
Karen Wazen Launches First Standalone Boutiques in Cairo
-
Phoenix Symphony Resumes Performances Amid Financial Uncertainty
-
Municipal Elections: How Service Failure Becomes a Public Health Crisis in South Africa
-
Turkish Energy Minister Highlights Qatar as Key Partner for Regional and Global Energy Security
-
Rene Eyre Revisits Autobiographical Performance 'Say A Little Prayer' in London
-
London Museum Granted 24/7 License Ahead of November Opening
-
UAE's HCT Holds Record Graduation and Announces Major Training Expansion
-
Dana White Confirms Flight to Washington for Trump Meeting on Press Secretary Role
-
NASA Awards $10B Lunar Contract Framework to SpaceX, Blue Origin
-
Dengue Fever Expands Into High Himalayas as Climate Change Warms Nepal
-
Katy Perry Tells Fans Ex-Husband Russell Brand 'Should Be in Jail' During UK Concert
-
IoT Refrigerator Hacks Disrupt Blood Labs and Supermarkets Across Europe and US
Novartis says buoyed by new treatments in second quarter
Swiss pharmaceuticals giant Novartis said Tuesday that group sales exceeded expectations in the second quarter of 2026, on the back of a range of new products.
Novartis said in a statement that sales in the period from April to June rose by three percent to $14.4 billion (12.6 billion euros), compared with the second quarter of 2025.
That was slightly higher than the $14 billion forecast by analysts polled by Swiss agency AWP.
The Basel-based group is facing the expiry of patents for a number of its drugs, including Entresto, a flagship treatment for heart failure.
In 2025, Entresto alone generated annual sales of $7.7 billion, even though its sales had already fallen sharply in the fourth quarter after its patent expired in the United States in July of that year.
Rhapsido, a treatment for chronic rashes that was approved in the US last September and then in the European Union at the end of April, has already generated $64 million in sales, Novartis said.
Net profit fell by 19 percent to $3.2 billion, hit by higher interest and tax expenses, the group explained.
Novartis confirmed its targets for 2026 and said it is still aiming for "low single-digit" sales growth for the whole year.
noo/nth/spm/yad
R.J.Fidalgo--PC
